AZ replants R&D roots in China, goes all-in on innovation
AstraZeneca throws weight behind China innovation while several peers focus on commercialization
In a big week for MNCs in China, AstraZeneca defined the latest move in its China strategy with an ‘all-in’ approach to innovation that goes full throttle by fostering R&D, AI and company formation.
As MNCs twist and turn on how best to participate in China’s growing biopharma sector and tap its increasingly important market, AstraZeneca plc (LSE:AZN; NYSE:AZN) is charting a different course from some its peers.
AZ’s Nov. 6 announcement of a $1 billion-targeted fund to invest in innovative healthcare companies in or focused on China, coupled with a new R&D center, an AI center and a slew of licensing deals, sees the company take an active role in fostering the growth of the emerging ecosystem.
“The new fund will inject vitality into the small